公开(公告)号：US11366312B2

公开(公告)日：2022-06-21

申请号：US17267856

申请日：2019-08-12

申请人： Miltenyi Biotec B.V. & CO. KG

发明人： Rainer Uhl

IPC分类号： G02B27/00 ,  G02B21/02 ,  G02B21/06 ,  G02B21/16 ,  G02B21/36 ,  G02B27/14 ,  H04N5/225

摘要： There is provided a microscope device comprising a microscope objective (12), a first light source (18) for transmitted light illumination of the sample (16) with light within a first spectral range and a second light source (20) for transmitted light illumination of the sample with light within a second spectral range different from the first spectral range, a tube lens (22) for forming a sample-image from the light collected by the microscope objective, a first camera detector (32) for detecting light within the first spectral range, a second camera detector (34) for detecting light within the second spectral range, a dichroic beam splitter (24) in the image beam path (26) between the tube lens and the detectors, and an analyzer unit (44), The beam splitter reflects light within the first spectral range onto the first detector and transmits light within the second spectral range onto the second detector, and wherein the analyzer unit is configured to combine a first image of the sample recorded by the first camera and a second image of the sample recorded by the second camera so as to generate a total sample image with enhanced contrast.

公开(公告)号：US20210301273A1

公开(公告)日：2021-09-30

申请号：US17264748

申请日：2019-07-26

申请人： Miltenyi Biotec B.V. & Co. KG

发明人： Skander Elleuche ,  Sarah Schmitz ,  Stefan Miltenyi ,  Volker Nolle

IPC分类号： C12N9/22 ,  C12N9/96 ,  G01N1/40

摘要： The present invention provides a composition comprising an isolated polypeptide having non-specific nuclease (NSN) activity for degrading nucleic acids comprising or consisting of at least 70% amino acid sequence identity to SEQ ID NO:2, wherein said polypeptide has NSN activity in a solution of about 4° C., and a cation complexing agent such as EDTA. Said composition may have preferentially a neutral to basic pH. A kit comprising said composition and a method using said composition are also disclosed.

公开(公告)号：US20210173203A1

公开(公告)日：2021-06-10

申请号：US17267856

申请日：2019-08-12

申请人： Miltenyi Biotec B.V. & CO. KG

发明人： Rainer UHL

IPC分类号： G02B27/00 ,  G02B21/06 ,  G02B21/02 ,  G02B21/36 ,  G02B21/16 ,  G02B27/14 ,  H04N5/225

摘要： There is provided a microscope device comprising a microscope objective (12), a first light source (18) for transmitted light illumination of the sample (16) with light within a first spectral range and a second light source (20) for transmitted light illumination of the sample with light within a second spectral range different from the first spectral range, a tube lens (22) for forming a sample-image from the light collected by the microscope objective, a first camera detector (32) for detecting light within the first spectral range, a second camera detector (34) for detecting light within the second spectral range, a dichroic beam splitter (24) in the image beam path (26) between the tube lens and the detectors, and an analyzer unit (44), The beam splitter reflects light within the first spectral range onto the first detector and transmits light within the second spectral range onto the second detector, and wherein the analyzer unit is configured to combine a first image of the sample recorded by the first camera and a second image of the sample recorded by the second camera so as to generate a total sample image with enhanced contrast.

公开(公告)号：US20210079344A1

公开(公告)日：2021-03-18

申请号：US17011746

申请日：2020-09-03

申请人： Miltenyi Biotec B.V. & Co. KG

发明人： Andreas Bosio ,  Andrej Smiyakin

IPC分类号： C12N5/079 ,  G01N33/569 ,  A61K35/30

摘要： The present invention discloses an in vitro method for the generation of a cell composition comprising or consisting of ventral midbrain dopaminergic progenitor cells from a cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps of A) differentiating said pluripotent and/or multipotent stem cells into ventral dopaminergic progenitor cells, thereby generating a cell composition comprising ventral dopaminergic progenitor cells comprising ventral midbrain dopaminergic progenitor cells and ventral hindbrain dopaminergic progenitor cells, and B) Enriching CD117 positive cells from said cell composition comprising ventral dopaminergic progenitor cells by using an antigen binding molecule specific for the CD117 antigen, thereby generating said cell composition comprising or consisting of ventral midbrain dopaminergic progenitor cells. Cell compositions obtainable by said method are also disclosed.

公开(公告)号：US10925944B2

公开(公告)日：2021-02-23

申请号：US15510222

申请日：2015-09-10

申请人： MILTENYI BIOTEC B.V. & CO. KG

发明人： Jolanda De Vries ,  Carl Figdor ,  Ghaith Bakdash

IPC分类号： A61K35/15 ,  A61K39/00 ,  C12N5/0784 ,  A61K35/12

摘要： The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c(BDCA-1)+/CD19− dendritic cells, wherein CD1c(BDCA-1)+/CD19− dendritic cells are depleted for CD1c(BDCA-1)+/CD19−/CD14+ cells.

公开(公告)号：US20210018498A1

公开(公告)日：2021-01-21

申请号：US17035833

申请日：2020-09-29

申请人： Miltenyi Biotec B.V. & Co. KG

发明人： Jennifer PANKRATZ ,  Christian DOSE ,  Mario ASSENMACHER

IPC分类号： G01N33/542 ,  G01N33/53 ,  G01N33/537

摘要： The invention is directed to a Method for detecting a target moiety in a sample of biological specimens by: a) providing at least one conjugate with the general formula (I) An-P-Bm-Cq-Xo  (I) with A: antigen recognizing moiety; P: enzymatically degradable spacer; B: first binding moiety C second binding moiety X: detection moiety; n, m, q, o integers between 1 and 100, wherein B and C are non-covalently bound to each other and A and B are covalently bound to P b) labelling the target moiety recognized by the antigen recognizing moiety A with at least one conjugate c) detecting the labelled target moiety via detecting moiety X d) cleaving Cq-Xo by disrupting the non-covalent bond between Bm and Cq from the labelled target moiety e) cleaving the binding moiety Bm from the labelled target moiety by enzymatically degrading spacer P. The method is useful to identify target moieties on the biological specimens. The biological specimens detected by the conjugate can be subsequently removed from the sample.

公开(公告)号：US10705091B2

公开(公告)日：2020-07-07

申请号：US16675072

申请日：2019-11-05

申请人： Miltenyi Biotec GmbH

发明人： Stefan Miltenyi ,  Winfried Schimmelpfennig ,  Holger Lantow ,  Niklas Elmar Neuschaefer ,  Martin Biehl ,  Eiad Kabaha ,  Juergen Schulz

IPC分类号： B01L3/00 ,  C12M3/00 ,  G01N33/58 ,  C12M1/36 ,  C12M1/00 ,  C12N5/0783 ,  A61M1/36 ,  C12N5/077 ,  C12N5/0789 ,  B01D15/38 ,  B04B7/08 ,  B04B1/12 ,  B04B5/10 ,  B04B5/04 ,  B04B5/00 ,  B01D21/26 ,  C12M1/26 ,  G01N35/00 ,  A61M1/02 ,  B03C1/034 ,  B03C1/033 ,  B03C1/027 ,  B03C1/00 ,  B03C1/032 ,  B04B13/00 ,  B03C1/28 ,  C12N5/00

摘要： The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

公开(公告)号：US20240316192A1

公开(公告)日：2024-09-26

申请号：US18429213

申请日：2024-01-31

申请人： Miltenyi Biotec B.V. & Co. Kg

发明人： Michael Lutteropp ,  Anne Richter ,  Andrew Kaiser ,  Mario Assenmacher ,  Stefan Miltenyi

IPC分类号： A61K39/395 ,  A61K35/12 ,  A61K38/17 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K35/12 ,  A61K38/1774 ,  A61K39/0005 ,  A61K2035/124 ,  A61K2039/5156

摘要： This disclosure provides a system for preventing or reducing side effects in a patent undergoing immunotherapy to remove diseased cells that express a target antigen: for example, by CAR T cell therapy. Side effects can ensue from concurrent depletion of hematopoietic cells bearing the same target antigen. A population of engineered hematopoietic cells is prepared by obtaining healthy hematopoietic cells from the patient or a third party donor, and using them to produce engineered hematopoietic cells. The engineered cells either do not express the target antigen, express it at a lower density, or express it in a modified form. The engineered hematopoietic cells are formulated for administration to the patient, whereupon they reconstitute hematopoietic cell function, thereby preventing or reducing the side effects.

公开(公告)号：US20240307533A1

公开(公告)日：2024-09-19

申请号：US18732517

申请日：2024-06-03

申请人： Miltenyi Biotec B.V. & Co. Kg

发明人： Michael Lutteropp ,  Anne Richter ,  Andrew Kaiser ,  Mario Assenmacher ,  Stefan Miltenyi

IPC分类号： A61K39/395 ,  A61K35/12 ,  A61K38/17 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K35/12 ,  A61K38/1774 ,  A61K39/0005 ,  A61K2035/124 ,  A61K2039/5156

摘要： This disclosure provides a system for preventing or reducing side effects in a patent undergoing immunotherapy to remove diseased cells that express a target antigen: for example, by CAR T cell therapy. Side effects can ensue from concurrent depletion of hematopoietic cells bearing the same target antigen. A population of engineered hematopoietic cells is prepared by obtaining healthy hematopoietic cells from the patient or a third party donor, and using them to produce engineered hematopoietic cells. The engineered cells either do not express the target antigen, express it at a lower density, or express it in a modified form. The engineered hematopoietic cells are formulated for administration to the patient, whereupon they reconstitute hematopoietic cell function, thereby preventing or reducing the side effects.

公开(公告)号：US20240248076A1

公开(公告)日：2024-07-25

申请号：US18443732

申请日：2024-02-16

申请人： Miltenyi Biotec B.V. & Co. KG

发明人： Melanie Jungblut ,  Andreas Bosic ,  Sebastian Knobel ,  Agnete Kirkeby ,  Malin Parmar

IPC分类号： G01N33/50 ,  G01N33/58

CPC分类号： G01N33/5005 ,  G01N33/58

摘要： The present invention provides an in-vitro method for analyzing a cell composition comprising human floorplate mesDA progenitor cells, the method comprising a) contacting the cells of said cell composition or the cells of a sample thereof with antigen binding molecules specific for the antigens FOXA2, OTX2, PAX6, and NKX6.1, thereby labeling the cells of said cell composition or of said sample, b) determining the percentage of said cells that are labelled with said antigen binding molecules for each of said antigens, and wherein the cells of said cell composition qualify as human floorplate mesDA progenitor cells if the protein expression profile of said cells is: 80-100% of said cells are positive for FOXA2, 80-100% of said cells are positive for OTX2, less than 10% of said cells are positive for PAX6, and less than 10% of said cells are positive for NKX6.1. A kit comprising said antigen binding molecules for use in said method is also provided.